Scott Wardwell

5.8k citations

22 papers · 2.4k indexed · 1 hit paper · h-index 15

Impact in

Immunology top 5%
- Immune Response and Inflammation
- interferon and immune responses
Molecular Biology top 5%
- Cell death mechanisms and regulation
- Inflammasome and immune disorders
- Fibroblast Growth Factor Research
- PI3K/AKT/mTOR signaling in cancer

Papers in

Hematology 6
- Chronic Myeloid Leukemia Treatments 5
Genetics 4

Co-authors: Victor M. Rivera Tim Clackson Frank Wang Hamish Allen Subhashis Banerjee Daniel E. TraceyPing LiMichael Paskind
Journals: Cancer Research (5 papers)Molecular Cancer Therapeutics (4 papers)Blood (4 papers)Clinical Cancer Research (1 paper)Science (1 paper)
Partner nations: United States Switzerland

In The Last Decade

Scott Wardwell

22 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock 1995 · 1.2k citations

Peers

Countries citing papers authored by Scott Wardwell

Since Specialization

Citations

This map shows the geographic impact of Scott Wardwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Wardwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Wardwell more than expected).

Fields of papers citing papers by Scott Wardwell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Wardwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Wardwell. The network helps show where Scott Wardwell may publish in the future.

Co-authors

The 25 scholars most cited alongside Scott Wardwell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Scott Wardwell Line = papers co-authored together Scott Wardwell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC Cancer Research ·Luz Tavera, Stefanie S. Schalm, John Campbell, Jian Guo, Clare Medendorp, Maxine Chen, Faris Albayya, Tom Dineen, Zhuo Zhang, Maria S. Iliou, Ebby Job, Nisha Perez, Yoav Timsit, Scott Wardwell, Katie McGinn, Richard Woessner, Chiara Conti	2022	9
2	RET fusions observed in lung and colorectal cancers are sensitive to ponatinib Oncotarget ·Joseph M. Gozgit, Tzu-Hsiu Chen, Youngchul Song, Scott Wardwell, Frank Wang, Jie Cai, Henry Li, Henrik Edgren, Victor M. Rivera, Justin R. Pritchard	2018	19
3	Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models Cancer Research ·Sen Zhang, Sara Nadworny, Scott Wardwell, Lindsey Eichinger, Biplab Das, Emily Y. Ye, John Hodgson, Victor M. Rivera	2015	9
4	Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants Cancer Research ·Wei‐Sheng Huang, Feng Li, Lisi Cai, Yongjin Xu, Sen Zhang, Scott Wardwell, Yaoyu Ning, Anna Kohlmann, Tianjun Zhou, Emily Y. Ye, Xiaotian Zhu, Narayana I. Narasimhan, Tim Clackson, Victor M. Rivera, David C. Dalgarno, William C. Shakespeare	2015	2
5	Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients Clinical Cancer Research ·Andrew P. Garner, Joseph M. Gozgit, Rana Anjum, Sadanand Vodala, Alexa B. Schrock, Tianjun Zhou, César Serrano, Grant Eilers, Mei‐Jun Zhu, Julia Ketzer, Scott Wardwell, Yaoyu Ning, Youngchul Song, Anna Kohlmann, Frank Wang, Tim Clackson, Michael C. Heinrich, Jonathan A. Fletcher, Sebastian Bauer, Victor M. Rivera	2014	123
6	Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models Cancer Chemotherapy and Pharmacology ·Joseph M. Gozgit, Rachel M. Squillace, Matthew Wongchenko, David F. Miller, Scott Wardwell, Qurish K. Mohemmad, Narayana I. Narasimhan, Frank Wang, Tim Clackson, Victor M. Rivera	2013	50
7	Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models Molecular Cancer Therapeutics ·Joseph M. Gozgit, Matthew J. Wong, Lauren Moran, Scott Wardwell, Qurish K. Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Tim Clackson, Victor M. Rivera	2012	273
8	Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models International Journal of Oncology ·Rachel M. Squillace, David F. Miller, Scott Wardwell, Frank Wang, Tim Clackson, Victor M. Rivera	2012	27
9	Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC Cancer Research ·Victor M. Rivera, Frank Wang, Rana Anjum, Sen Zhang, Rachel M. Squillace, Jeffrey Keats, David F. Miller, Yaoyu Ning, Scott Wardwell, Lauren Moran, Juan J. Miret, Narayana I. Narasimhan, David C. Dalgarno, Tim Clackson, William C. Shakepeare	2012	36
10	Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models Molecular Cancer Therapeutics ·Rachel M. Squillace, David F. Miller, Michelle Cookson, Scott Wardwell, Lauren Moran, David E. Clapham, Frank Wang, Tim Clackson, Victor M. Rivera	2011	40
11	Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens Molecular Cancer Therapeutics ·Victor M. Rivera, Rachel M. Squillace, David F. Miller, Lori Berk, Scott Wardwell, Yaoyu Ning, Roy M. Pollock, Narayana I. Narasimhan, John D. Iuliucci, Frank Wang, Tim Clackson	2011	87
12	Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies Molecular Cancer Therapeutics ·Joseph M. Gozgit, Matthew J. Wong, Scott Wardwell, Jeffrey Tyner, Marc Loriaux, Qurish K. Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Brian Druker, Tim Clackson, Victor M. Rivera	2011	110
13	Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) Cancer Research ·Sen Zhang, Frank Wang, Jeffrey Keats, Yaoyu Ning, Scott Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Xiaotian Zhu, Juan J. Miret, David C. Dalgarno, Narayana I. Narasimhan, Tim Clackson, William C. Shakespeare, Victor M. Rivera	2010	44
14	Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML). Blood ·Victor M. Rivera, Qihong Xu, Frank Wang, J. T. Snodgrass, Thomas O’Hare, Amie S. Corbin, Jeffrey Keats, Sarah D. Lamore, Yaoyu Ning, Scott Wardwell, Karin Russian, Marc I. Broudy, William C. Shakespeare, Brian Druker, John D. Iuliucci, Tim Clackson	2007	15
15	In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit Blood ·Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Yihan Wang, Chester A. Metcalf, Raji Sundaramoorthi, William C. Shakespeare, J. T. Snodgrass, Scott Wardwell, David C. Dalgarno, John D. Iuliucci, Tomi K. Sawyer, Michael C. Heinrich, Brian Druker, Michael W. Deininger	2005	47
16	In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT. Blood ·Amie S. Corbin, Shadmehr Demehri, Ian J. Griswold, Chester A. Metcalf, William C. Shakespeare, J. T. Snodgrass, Scott Wardwell, David C. Dalgarno, John D. Iuliucci, Tomi K. Sawyer, Brian Druker, Michael W. Deininger	2004	2
17	Regulation of Protein Secretion Through Controlled Aggregation in the Endoplasmic Reticulum Science ·Victor M. Rivera, Xiurong Wang, Scott Wardwell, Nancy L. Courage, Allen Volchuk, Terence P. Keenan, Dennis A. Holt, Michael Gilman, Lelio Orci, Frank Cerasoli, James E. Rothman, Tim Clackson	2000	271
18	Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock Cell ·Ping Li, Hamish Allen, Subhashis Banerjee, Simon Franklin, Linda Herzog, Cynthia G. Johnston, J. J. McDowell, Michael Paskind, Laura Rodman, Jochen Salfeld, E. Gene Towne, Daniel E. Tracey, Scott Wardwell, Wei Fang, Winnie W. Wong, Robert Kamen, Tara Seshadri Hit paper breakdown →	1995	1225
19	Effect of butyrate and corticosteroids on retinoblastoma in vitro and in vivo. PubMed ·Mitzi Howard, Scott Wardwell, Daniel M. Albert	1991	12
20	The Value of Nucleolar Organizer Regions in Uveal Melanoma American Journal of Ophthalmology ·Dennis M. Marcus, Jeffrey B. Minkovitz, Scott Wardwell, Daniel M. Albert, (unknown)	1990	23

About Scott Wardwell

Scott Wardwell is a scholar working on Hematology, Genetics, Gastroenterology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 2.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (6 papers), Chronic Myeloid Leukemia Treatments (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Mast cells and histamine (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Eosinophilic Disorders and Syndromes (3 papers), Kruppel-like factors research (2 papers) and Cancer therapeutics and mechanisms (2 papers). The work is most often cited by research in Immunology (644 citations), Molecular Biology (1.6k citations), Hematology (241 citations), Gastroenterology (97 citations) and Oncology (386 citations). Scott Wardwell has collaborated with scholars based in United States and Switzerland. Frequent co-authors include Victor M. Rivera, Tim Clackson, Frank Wang, Hamish Allen, Subhashis Banerjee, Daniel E. Tracey, Ping Li, Michael Paskind, Jochen Salfeld and E. Gene Towne. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Blood, Clinical Cancer Research and Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact